Observed and expected cancers and SIRs among Danish patients diagnosed with PV during 1977-2008 and followed for new primary cancers
| . | Cancers observed, n . | Cancers expected, n . | SIR (95% CI) . |
|---|---|---|---|
| Oropharyngeal | 14 | 8.9 | 1.6 (0.9-2.6) |
| Esophagus | 15 | 6.4 | 2.4 (1.4-4.0) |
| Stomach | 12 | 12.0 | 1.0 (0.5-1.7) |
| Colon | 41 | 43.6 | 0.9 (0.7-1.3) |
| Rectum | 21 | 23.0 | 0.9 (0.6-1.4) |
| Liver, primary | 11 | 5.1 | 2.2 (1.1-3.9) |
| Gall bladder | 4 | 3.6 | 1.1 (0.3-2.9) |
| Pancreas | 21 | 13.9 | 1.5 (0.9-2.3) |
| Lung, primary | 127 | 67.9 | 1.9 (1.6-2.2) |
| Breast | 43 | 37.7 | 1.1 (0.8-1.5) |
| Cervix uteri | 6 | 3.5 | 1.7 (0.6-3.8) |
| Corpus uteri | 14 | 8.7 | 1.6 (0.9-2.7) |
| Ovary | 4 | 6.7 | 0.6 (0.2-1.5) |
| Prostate | 64 | 50.2 | 1.3 (1.0-1.6) |
| Kidney | 17 | 9.0 | 1.9 (1.1-3.0) |
| Urinary tract | 50 | 35.3 | 1.4 (1.1-1.9) |
| Malignant melanoma | 17 | 10.1 | 1.7 (1.0-2.7) |
| Nonmelanoma skin cancer | 146 | 88.5 | 1.7 (1.4-1.9) |
| Eye | 3 | 1.0 | 3.1 (0.6-8.9) |
| Brain | 10 | 11.4 | 0.9 (0.4-1.6) |
| Carcinoma unspecified | 33 | 20.7 | 1.6 (1.1-2.2) |
| NonHodgkin lymphoma | 20 | 11.4 | 1.8 (1.1-2.7) |
| Lymphoid leukemia | 4 | 6.7 | 0.6 (0.2-1.5) |
| Multiple myeloma | 8 | 5.3 | 1.5 (0.7-3.0) |
| Myeloid leukemia | 55 | 3.4 | 16.0 (12.0-20.8) |
| Unspecified leukemia | 17 | 0.5 | 33.1 (19.3-53.0) |
| Myelodysplastic syndrome | 10 | 2.0 | 5.0 (2.4-9.2) |
| . | Cancers observed, n . | Cancers expected, n . | SIR (95% CI) . |
|---|---|---|---|
| Oropharyngeal | 14 | 8.9 | 1.6 (0.9-2.6) |
| Esophagus | 15 | 6.4 | 2.4 (1.4-4.0) |
| Stomach | 12 | 12.0 | 1.0 (0.5-1.7) |
| Colon | 41 | 43.6 | 0.9 (0.7-1.3) |
| Rectum | 21 | 23.0 | 0.9 (0.6-1.4) |
| Liver, primary | 11 | 5.1 | 2.2 (1.1-3.9) |
| Gall bladder | 4 | 3.6 | 1.1 (0.3-2.9) |
| Pancreas | 21 | 13.9 | 1.5 (0.9-2.3) |
| Lung, primary | 127 | 67.9 | 1.9 (1.6-2.2) |
| Breast | 43 | 37.7 | 1.1 (0.8-1.5) |
| Cervix uteri | 6 | 3.5 | 1.7 (0.6-3.8) |
| Corpus uteri | 14 | 8.7 | 1.6 (0.9-2.7) |
| Ovary | 4 | 6.7 | 0.6 (0.2-1.5) |
| Prostate | 64 | 50.2 | 1.3 (1.0-1.6) |
| Kidney | 17 | 9.0 | 1.9 (1.1-3.0) |
| Urinary tract | 50 | 35.3 | 1.4 (1.1-1.9) |
| Malignant melanoma | 17 | 10.1 | 1.7 (1.0-2.7) |
| Nonmelanoma skin cancer | 146 | 88.5 | 1.7 (1.4-1.9) |
| Eye | 3 | 1.0 | 3.1 (0.6-8.9) |
| Brain | 10 | 11.4 | 0.9 (0.4-1.6) |
| Carcinoma unspecified | 33 | 20.7 | 1.6 (1.1-2.2) |
| NonHodgkin lymphoma | 20 | 11.4 | 1.8 (1.1-2.7) |
| Lymphoid leukemia | 4 | 6.7 | 0.6 (0.2-1.5) |
| Multiple myeloma | 8 | 5.3 | 1.5 (0.7-3.0) |
| Myeloid leukemia | 55 | 3.4 | 16.0 (12.0-20.8) |
| Unspecified leukemia | 17 | 0.5 | 33.1 (19.3-53.0) |
| Myelodysplastic syndrome | 10 | 2.0 | 5.0 (2.4-9.2) |
Data are stratified according to cancer type.